Published in J Cell Physiol on March 01, 2007
LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev (2008) 3.46
The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31
Thrombospondins in cancer. Cell Mol Life Sci (2008) 2.08
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med (2012) 1.68
The thrombospondins. Cold Spring Harb Perspect Biol (2011) 1.52
Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc Res (2010) 1.45
Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal (2009) 1.40
The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47. Matrix Biol (2012) 1.34
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J (2009) 1.29
Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem (2010) 1.27
Thrombospondin-based antiangiogenic therapy. Microvasc Res (2007) 1.26
p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res (2011) 1.14
The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J Cell Commun Signal (2009) 1.11
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev (2013) 1.05
Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell (2007) 1.03
Heparin-induced cis- and trans-dimerization modes of the thrombospondin-1 N-terminal domain. J Biol Chem (2007) 1.00
The interaction of Thrombospondins with extracellular matrix proteins. J Cell Commun Signal (2009) 0.97
Extracellular matrix proteins and tumor angiogenesis. J Oncol (2010) 0.97
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther (2009) 0.97
Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets (2008) 0.97
Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and -9, and soluble VEGF. J Histochem Cytochem (2008) 0.94
Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. Int J Clin Oncol (2010) 0.90
Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease. Matrix Biol (2014) 0.90
Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer. Mol Cancer (2014) 0.88
DNA methylation profile distinguishes clear cell sarcoma of the kidney from other pediatric renal tumors. PLoS One (2013) 0.88
Deletion of heart-type cytochrome c oxidase subunit 7a1 impairs skeletal muscle angiogenesis and oxidative phosphorylation. J Physiol (2012) 0.88
Low level of low-density lipoprotein receptor-related protein 1 predicts an unfavorable prognosis of hepatocellular carcinoma after curative resection. PLoS One (2012) 0.86
Physiological Capillary Regression is not Dependent on Reducing VEGF Expression. Microcirculation (2016) 0.84
Expression of angiogenic basic fibroblast growth factor, platelet derived growth factor, thrombospondin-1 and their receptors at the porcine maternal-fetal interface. Reprod Biol Endocrinol (2011) 0.83
E2F-1 directly regulates thrombospondin 1 expression. PLoS One (2010) 0.83
Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett (2012) 0.83
Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer. Am J Transl Res (2015) 0.82
Counterbalancing forces: what is thrombospondin-1 doing in atherosclerotic lesions? Circ Res (2008) 0.81
Pregnancy-associated genes contribute to antiluteolytic mechanisms in ovine corpus luteum. Physiol Genomics (2013) 0.80
Chronic delivery of a thrombospondin-1 mimetic decreases skeletal muscle capillarity in mice. PLoS One (2013) 0.80
DLL4/Notch1 and BMP9 Interdependent Signaling Induces Human Endothelial Cell Quiescence via P27KIP1 and Thrombospondin-1. Arterioscler Thromb Vasc Biol (2015) 0.79
Identification of TAX2 peptide as a new unpredicted anti-cancer agent. Oncotarget (2015) 0.79
The Matricellular Receptor LRP1 Forms an Interface for Signaling and Endocytosis in Modulation of the Extracellular Tumor Environment. Front Pharmacol (2015) 0.78
Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals (Basel) (2010) 0.78
Molecular mechanisms of enhancing porcine granulosa cell proliferation and function by treatment in vitro with anti-inhibin alpha subunit antibody. Reprod Biol Endocrinol (2015) 0.77
Chronic effects of an anti-angiogenic thrombospondin-1 mimetic peptide, ABT-898, on female mouse reproductive outcomes. Reprod Biol Endocrinol (2016) 0.75
Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation. Front Physiol (2017) 0.75
Long-term gene therapy with thrombospondin 2 inhibits TGF-β activation, inflammation and angiogenesis in chronic allograft nephropathy. PLoS One (2013) 0.75
CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis. Oncotarget (2016) 0.75
Restructuring of the vascular bed in response to hemodynamic disturbances in portal hypertension. World J Hepatol (2016) 0.75
The thrombospondin-1 receptor CD36 is an important mediator of ovarian angiogenesis and folliculogenesis. Reprod Biol Endocrinol (2014) 0.75
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS One (2017) 0.75
Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer (2017) 0.75
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
The role of angiogenesis in tumor growth. Semin Cancer Biol (1992) 5.33
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med (2000) 5.05
Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest (1998) 4.00
CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol (1997) 3.52
The thrombospondins. Int J Biochem Cell Biol (2004) 3.01
Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med (2002) 2.97
Endogenous inhibitors of angiogenesis. Cancer Res (2005) 2.88
Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J (2001) 2.79
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A (2003) 2.20
Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem (2000) 2.18
Thrombospondins: structure and regulation of expression. FASEB J (1992) 2.04
Diverse roles for the LDL receptor family. Trends Endocrinol Metab (2002) 1.99
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica (2003) 1.97
Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res (1992) 1.90
Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol (2004) 1.77
Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol (2003) 1.76
Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem (2000) 1.58
The low-density lipoprotein receptor gene family: a cellular Swiss army knife? Trends Cell Biol (2002) 1.54
Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn (2003) 1.53
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A (2005) 1.51
Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer (2000) 1.51
Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci (2004) 1.40
Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis (1999) 1.31
Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology (2002) 1.30
Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol (1995) 1.30
Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate (2001) 1.29
The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem (1999) 1.23
Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2.TIMP-2 complex through a thrombospondin-independent mechanism. J Biol Chem (2004) 1.20
Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans. J Biol Chem (1995) 1.17
Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem (2004) 1.15
Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol (2001) 1.15
Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. J Cell Biochem (2002) 1.14
Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. Endocrinology (2004) 1.11
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood (2003) 1.07
Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res (1997) 1.07
Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photo-damage. J Invest Dermatol (2002) 1.05
The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology (2004) 1.04
Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int (2002) 1.02
Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum Reprod (2005) 1.01
Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. Adv Exp Med Biol (1995) 1.00
Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. Cancer Res (1997) 1.00
Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J Clin Endocrinol Metab (2001) 0.99
Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res (2002) 0.98
Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J Cell Biochem (2004) 0.98
Thombospondin-1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression is suppressed by estradiol. Mol Cancer Res (2004) 0.98
Vascular endothelial growth factor production in growing pig antral follicles. Biol Reprod (2000) 0.98
Role of rap in the biogenesis of lipoprotein receptors. Trends Cardiovasc Med (2000) 0.96
Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer (2005) 0.95
Expression and localisation of vascular endothelial growth factor and basic fibroblast growth factor during the final growth of bovine ovarian follicles. J Endocrinol (2000) 0.94
VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun (2005) 0.90
Regulation mechanism of selective atresia in porcine follicles: regulation of granulosa cell apoptosis during atresia. J Reprod Dev (2004) 0.89
Thrombospondin and vascular endothelial growth factor are cyclically expressed in an inverse pattern during bovine ovarian follicle development. Biol Reprod (2004) 0.89
Expression and localization of thrombospondin-1 and -2 and their cell-surface receptor, CD36, during rat follicular development and formation of the corpus luteum. Biol Reprod (2002) 0.89
Regulation of apoptosis in the atresia of dominant bovine follicles of the first follicular wave following ovulation. Reproduction (2005) 0.88
Tumor angiogenesis. J Investig Dermatol Symp Proc (2000) 0.88
Angiogenesis in the primate ovary. Reprod Fertil Dev (2001) 0.88
Structural organization of the receptor associated protein. Biochemistry (2003) 0.85
Relationship between blood flow and steroidogenesis in the rabbit corpus luteum. J Reprod Fertil (1988) 0.84
Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content and primary activation. Int J Biol Markers (2004) 0.84
Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance. Clin Exp Metastasis (2004) 0.82
Divergent Pseudomonas exotoxin A sensitivity in normal and transformed liver cells is correlated with low-density lipoprotein receptor-related protein expression. Toxicon (2001) 0.82
Neovascularization of the corpus luteum of rats during the estrus cycle. Pathol Int (1996) 0.79
Microvessel quantification in benign and malignant ovarian tumors. Int J Gynecol Cancer (2005) 0.76
Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell (2005) 7.41
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med (2005) 3.60
Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell (2009) 3.46
The thrombospondins. Int J Biochem Cell Biol (2004) 3.01
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31
Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol (2002) 2.28
The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol (2002) 2.22
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A (2003) 2.20
Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation (2005) 2.09
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Am J Pathol (2004) 1.88
Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol (2003) 1.76
Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta (2005) 1.76
SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem (2007) 1.68
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med (2012) 1.68
Dynamic reciprocity in the wound microenvironment. Wound Repair Regen (2011) 1.62
Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther (2004) 1.62
Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol (2005) 1.59
Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn (2003) 1.53
A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid (2009) 1.53
Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost (2003) 1.52
The thrombospondins. Cold Spring Harb Perspect Biol (2011) 1.52
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A (2005) 1.51
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res (2011) 1.47
Interactions between CD47 and thrombospondin reduce inflammation. J Immunol (2007) 1.46
A thrombospondin-dependent pathway for a protective ER stress response. Cell (2012) 1.45
Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res (2004) 1.42
Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9. J Leukoc Biol (2009) 1.41
Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci (2004) 1.40
Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal (2009) 1.40
Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis. Matrix Biol (2009) 1.40
Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins. J Biol Chem (2005) 1.37
Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest (2006) 1.35
Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood (2005) 1.35
Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b. Oncogene (2004) 1.34
The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat (2008) 1.32
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J (2009) 1.29
Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan. J Biol Chem (2007) 1.27
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist (2011) 1.27
Thrombospondin-based antiangiogenic therapy. Microvasc Res (2007) 1.26
Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell (2002) 1.26
The structures of the thrombospondin-1 N-terminal domain and its complex with a synthetic pentameric heparin. Structure (2006) 1.25
Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol (2008) 1.25
Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem (2006) 1.21
Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol (2007) 1.21
Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ Res (2010) 1.19
Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem (2004) 1.19
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18
Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice. Am J Pathol (2005) 1.17
Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. Am J Pathol (2008) 1.17
Improved vascular engraftment and graft function after inhibition of the angiostatic factor thrombospondin-1 in mouse pancreatic islets. Diabetes (2008) 1.17
Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes (2007) 1.15
The secreted protein thrombospondin 2 is an autocrine inhibitor of marrow stromal cell proliferation. J Bone Miner Res (2002) 1.15
Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2--deficient mice. Blood (2002) 1.14
Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol (2005) 1.14
Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A (2011) 1.13
Mice with a deletion in the first intron of the Col1a1 gene develop age-dependent aortic dissection and rupture. Circ Res (2003) 1.12
Thrombospondin 2 levels are increased in aged mice: consequences for cutaneous wound healing and angiogenesis. Matrix Biol (2004) 1.11
Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. Endocrinology (2004) 1.11
Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med (2011) 1.10
Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res (2005) 1.10
Morphologic and morphometric magnetic resonance imaging features of Doberman Pinschers with and without clinical signs of cervical spondylomyelopathy. Am J Vet Res (2006) 1.06
Thrombospondin-1-deficient mice are not protected from bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2010) 1.06
pH-sensitive polymers that enhance intracellular drug delivery in vivo. J Control Release (2002) 1.05
Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem (2004) 1.05
Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis (2003) 1.04
Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. Am J Pathol (2003) 1.04
Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head. Mol Cell Biol (2005) 1.03
Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell (2007) 1.03
Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol (2004) 1.02
Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. Blood (2005) 1.01
Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation (2009) 1.00
Heparin-induced cis- and trans-dimerization modes of the thrombospondin-1 N-terminal domain. J Biol Chem (2007) 1.00
A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res (2009) 0.99
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget (2010) 0.98
Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1. PLoS One (2008) 0.98
Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J Cell Biochem (2004) 0.98
The interaction of Thrombospondins with extracellular matrix proteins. J Cell Commun Signal (2009) 0.97
Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res (2007) 0.97
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther (2009) 0.97
Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol (2009) 0.97
Thrombospondin-1: an islet endothelial cell signal of importance for β-cell function. Diabetes (2011) 0.96
Reduced expression of thrombospondins and craniofacial dysmorphism in mice overexpressing Fra1. J Bone Miner Res (2006) 0.96
Megakaryocytes require thrombospondin-2 for normal platelet formation and function. Blood (2003) 0.95
Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood (2011) 0.95
Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model. Cancer Res (2005) 0.95
The crystal structure of the signature domain of cartilage oligomeric matrix protein: implications for collagen, glycosaminoglycan and integrin binding. FASEB J (2009) 0.94
MicroRNA-140 expression during chondrogenic differentiation of equine cord blood-derived mesenchymal stromal cells. Stem Cells Dev (2013) 0.94
Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and -9, and soluble VEGF. J Histochem Cytochem (2008) 0.94
The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood (2013) 0.93
Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res (2005) 0.93